RRP9 Inhibitors
RRP9 inhibitors encompass a range of chemical compounds that indirectly reduce the functional activity of the RRP9 protein, primarily by affecting ribosome biogenesis and rRNA processing. These inhibitors act on various stages of ribosome assembly and general protein synthesis, thereby diminishing the demand for RRP9's role in the maturation of the 18S rRNA component of the ribosome. For example, Cycloheximide and Homoharringtonine block translational elongation and initiation, respectively, reducing the cellular requirement for new ribosomes and, by extension, the processing activity of RRP9. Rapamycin, through its inhibition of mTOR signaling, downregulates ribosomal protein synthesis, which in turn diminishes the need for RRP9's assembly function. Actinomycin D and BMH-21 directly inhibit rRNA transcription, which decreases the substrate availability for RRP9, thereby indirectly reducing its activity in rRNA maturationRRP9 inhibitors consist of a selection of chemical compounds that, through various mechanisms, indirectly decrease the activity of the RRP9 protein, which is crucial for the maturation of 18S rRNA within the small subunit (SSU) processome. Cycloheximide and homoharringtonine target protein synthesis; by inhibiting translational elongation and initiation, they reduce the cellular need for ribosome production, thereby diminishing the need for RRP9's role in 18S rRNA processing.
Furthermore, actinomycin D, BMH-21, and CX-5461 directly inhibit rRNA transcription, which leads to a reduction in RRP9's function due to decreased substrate availability. Mycophenolic acid and fluorouracil disrupt nucleotide synthesis and metabolism, impacting the production and processing of rRNA and thus indirectly diminishing the biological role of RRP9. The collective action of these compounds results in a comprehensive downregulation of RRP9's involvement in ribosome assembly by targeting the pathways that govern ribosome production and protein synthesis, thereby leading to an indirect inhibition of RRP9 activity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by preventing translational elongation. This leads to a reduced demand for ribosome production, indirectly diminishing RRP9 activity by reducing the need for 18S rRNA processing. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR signaling, which is crucial for ribosome biogenesis. By inhibiting mTOR, ribosomal protein synthesis is downregulated, indirectly diminishing RRP9's role in ribosome assembly. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D binds to DNA and inhibits RNA polymerase, particularly during the transcription of rRNA. This diminishes the production of 18S rRNA, thereby reducing RRP9's functional role in rRNA maturation. | ||||||
BMH-21 | 896705-16-1 | sc-507460 | 10 mg | $165.00 | ||
BMH-21 intercalates into DNA and inhibits RNA polymerase I, leading to the degradation of the polymerase and a decrease in rRNA synthesis. This indirectly diminishes the functional activity of RRP9 by reducing its substrate availability. | ||||||
CX-5461 | 1138549-36-6 | sc-507275 | 5 mg | $240.00 | ||
CX-5461 inhibits RNA polymerase I-mediated rRNA synthesis, leading to a decreased need for SSU processome activity and thus diminishing RRP9's role in the pre-ribosomal complex. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
Mycophenolic acid inhibits inosine monophosphate dehydrogenase, which is crucial for guanine nucleotide synthesis. Reduced guanine nucleotide pools indirectly affect rRNA synthesis and processing, diminishing the demand for RRP9 activity. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide has been shown to impair the assembly of RNA polymerase II pre-initiation complexes, indirectly reducing mRNA synthesis for ribosomal proteins and thereby diminishing RRP9's role in ribosome assembly. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib, a proteasome inhibitor, would lead to an accumulation of misfolded proteins, triggering the unfolded protein response and potentially reducing ribosomal biogenesis, indirectly affecting RRP9's functional role. | ||||||
Homoharringtonine | 26833-87-4 | sc-202652 sc-202652A sc-202652B | 1 mg 5 mg 10 mg | $51.00 $123.00 $178.00 | 11 | |
Homoharringtonine inhibits protein synthesis initiation at the ribosome and could, therefore, reduce the demand for new ribosomes, indirectly diminishing the functional activity of RRP9. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
Fluorouracil is metabolized to nucleotide analogues that can inhibit thymidylate synthase, indirectly leading to a reduction in rRNA synthesis and processing, thus affecting RRP9's role. | ||||||